Article Text

Download PDFPDF
Polypoidal choroidal vasculopathy in Caucasian patients with presumed age-related macular degeneration
  1. Colin S Tan1,2,
  2. Wei Kiong Ngo1,2,
  3. Kai Xiong Cheong1,
  4. Tock Han Lim1,2
  1. 1 National Healthcare Group Eye Institute, Singapore, Singapore
  2. 2 Fundus Image Reading Center, National Healthcare Group Eye Institute, Singapore
  1. Correspondence to Dr Colin S H Tan, National Healthcare Group Eye Institute, Tan Tock Seng Hospital, 11 Jalan Tan Tock Seng, Singapore 308433, Singapore; Colintan_eye{at}

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

We read with interest the article by Hatz and Prünte1 describing the frequency of polypoidal choroidal vasculopathy (PCV) among Caucasian patients treated for presumed age-related macular degeneration (AMD). We wholeheartedly agree with the authors that differentiation between PCV and choroidal neovascularisation secondary to typical AMD at initial clinical presentation is important, because this distinction may alter the management decisions and influence the eventual visual outcome.

While the prevalence of PCV in this study is generally higher than those previously reported in Caucasian populations, it is possible that the frequency of PCV in this series may have been even higher if indocyanine green angiography (ICGA) had been performed at baseline. In this study, the authors included patients who were evaluated with ICGA only after receiving ≥8 ranibizumab injections. Prior to evaluation with ICGA, the patients who were eventually diagnosed with …

View Full Text


  • Contributors CST, WKN and KXC were involved in the literature search and writing of the article. CST and THL were involved in the reviewing and approving the article.

  • Competing interests CST receives research funding from the National Healthcare Group Clinician Scientist Career Scheme Grant (CSCS/12005) and travel support from Bayer (South East Asia) Pte Ltd. THL receives travel support from Novartis, Bayer and Heidelberg Engineering.

  • Provenance and peer review Not commissioned; externally peer reviewed.